Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2010
Cognitive impairment and anticholinergic therapy in patients with Parkinson's diseases
7th International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinson' s Disease (MDPD) -
The dual dopaminergic and non-dopaminergic actions of safinamide improve motor and depressive symptoms in patients with mid-late stage Parkinson ' s disease
V Lucini, R Borgohain, N A. Mehta, O Bajenaru, R Quatrale,
7th International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinson' s Disease (MDPD) -
Adjuvant activity of the novel sodium channel blocker NW-
E. Izzo, A. Ieraci, S. Meli, P. Salvati,
Neuroscience 2010 - 40th annual meeting, Nov. 13-17
Effects of safinamide as add-on to L-dopa on motor and depressivesymptoms in patients with mid- to late-stage Parkinson's disease
R Borgohain, N A. Mehta, O A. Bajenaru, R Quatrale, V Lucini,
2nd World Parkinson Conference (WPC) -
Effect of safinamide on dyskinesia in patients with mid- to late-stage Parkinson's disease: data from a post-hoc analysis
M Bhatt, D Chirileanu, C Meshram, P Stanzione, E Forrest, V Lucini, for the Study 016 Investigators
2nd World Parkinson Conference (WPC) -
Predicting exposure and response to safinamide in Parkinson's disease using population pharmacokinetic and pharmacodynamic modelling.
M Campioni, S Kroesser, M M. Thapar, S C. Hayes,
2nd World Parkinson Conference (WPC) -
Effects of safinamide as add-on to L-dopa on symptom severity and aspects of daily living in patients with mid- to late-stage Parkinson's disease
J Szasz, R Borgohain, M Bhatt, S Rossetti, V Lucini,
2nd World Parkinson Conference (WPC) -
Safinamide improves motor function without worsening troublesome dyskinesia as add-on therapy in L-dopa-treated patients with mid- to late-stage Parkinson's disease
C Meshram, M Bhatt, D Chirileanu, P Stanzione, V Lucini, S Rossetti,
14th Congress of the European Federation of Neurological Societies (EFNS) - September 25-28, 2010
Cognitive impairment in patients with mid- to late-stage Parkinson's disease
S De Santi,
14th Congress of the European Federation of Neurological Societies (EFNS) - September 25-28, 2010 -
L. Gregoire, A. Roach , T. Di Paolo
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Cognitive deficits in patients with mid- to late-stage Parkinson's disease
Susan M De Santi, PhD, Ravi Anand, MD, Valentina Lucini, MD, Patricia Rice, PhD and the Study 016Investigators
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
SETTLE study design: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's disease
Anthony H.V. Schapira, Susan Fox, Robert Hauser, Joseph Jankovic, Jaime Kulisevsky, Rajesh Pahwa,Werner Poewe, Florian von Raison, Christopher Kenney, Bruno Musch
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late Parkinson's disease
Chandrashekhar M Meshram, MD, Mohit Bhatt, MD, Dana Chirileanu, MD, Paolo Stanzione, MD, Valentina
Lucini, MD, Stefano M Rossetti, MD, Ravi Anand, MD and the Study 016 Investigators
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease
Rupam Borgohain, MD, Neeta A Mehta, MD, Ovidiu A Bajenaru, MD, Rocco Quatrale, MD, Valentina Lucini,MD, Ravi Anand, MD and the Study 016 investigators
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
MOTION (safinaMide add-On To dopamine agonist in early Idiopathic ParkinsON's disease) study design: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide
Paolo Barone, Hubert H. Fernandez, Joaquim J. Ferreira, Thomas Mueller, Marie Saint-Hilaire, Mark Stacy, Eduardo Tolosa, Florian von Raison, Christopher Kenney, Bruno Muschmide
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Population Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson's Disease
M. Campioni , S. Kroesser, M.M. Thapar , S.C. Hayes, E. Gibiansky, V. Lucini R. Anand
PAGE (Population Approach Group Europe) conference, Berlin, 8-11 June 2010
Adjuvant activity of the novel sodium channel blocker NW-3509 in combination therapy with antipsychotics
Emanuela Izzo, Alessandro Ieraci, Sara Meli, Marco Bortolato, Roberto Frau, Valentina Bini, Patricia Salvati, Ravi Anand
XXVII Congress of the CINP (International College of Neuropsychopharmacology 6-10 June 2010 -Hong Kong
Ion channel blockers for the treatment of neuropathic pain
Elena Colombo, Simona Francisconi, Laura Faravelli, Emanuela Izzo, Paolo Pevarello
Future Medicinal Chemistry, May 2010, Vol. 2, No. 5, Pages 803-842
Effect of safinamide on levodopa-induced dyskinesia in patients with Parkinson's disease
M. Bhatt, D. Chirileanu, C. Meshram, P. Stanzione, E. Forrest, V. Lucini for the Study 016 Investigators
62nd AAN Annual Meeting - April 10 -17, 2010 TORONTO, CANADA